Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL-Reference-Cited by-同舟云学术

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

Published:2020-03-05 Issue:2 Volume:35 Page:522-533
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hartert Keenan T.,Wenzl Kerstin,Krull Jordan E.,Manske Michelle,Sarangi Vivekananda,Asmann Yan,Larson Melissa C.,Maurer Matthew J.^ORCID,Slager Susan,Macon William R.,King Rebecca L.,Feldman Andrew L.^ORCID,Gandhi Anita K.,Link Brian K.,Habermann Thomas M.,Yang Zhi-Zhang,Ansell Stephen M.,Cerhan James R.^ORCID,Witzig Thomas E.^ORCID,Nowakowski Grzegorz S.,Novak Anne J.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0766-4.pdf

Reference62 articles.

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J Clin. 2018;69:7–34.

3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

4. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.

5. Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017;179:50–60.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation;Nature Communications;2024-08-08

2. Adult-Onset Systemic Chronic Active Epstein-Barr Virus Disease: A Case Report Highlighting Unique Immunophenotype and Novel Molecular Insights in the Context of Chronic HBV Hepatitis;Hemato;2024-07-30

3. Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data;Blood Cancer Journal;2024-07-04

4. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL;Blood Cancer Journal;2024-06-20

5. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes;Targeted Oncology;2024-04-21